Veracyte | VCYT - Operating Expenses


Veracyte reported $119.99M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
Agenus USD -221.22M 241.03M Mar/2026
Agilent USD 1.44B 9M Mar/2026
Anika Therapeutics USD 133.9M 103.93M Mar/2026
Arrowhead Research USD 215M 8.23M Mar/2026
Bruker USD 813.2M 87.7M Mar/2026
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Illumina USD 852M 51M Mar/2026
Intrexon USD 61.56M 26.1M Jun/2024
Karyopharm Therapeutics USD 51.92M 9.9M Dec/2025
Laboratory Of America USD 3.13B 6.3M Mar/2026
Ligand Pharmaceuticals USD 34.35M 5.27M Mar/2026
Myriad Genetics USD 212.8M 16.2M Dec/2025
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Roche Holding CHF 21.01B 10.84B Dec/2025
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Siemens EUR 16.57B 2.29B Dec/2025
Sonic Healthcare AUD 4.23B 2.14B Dec/2024
Thermo Fisher Scientific USD 9.09B 821M Mar/2026
Veracyte USD 119.99M 3.99M Mar/2026
Waters USD 1.12B 457.15M Mar/2026